Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Clarity Pharmaceuticals has announced their COBRA study’s selection as a Top-Rated Oral Presentation at the EANM 2024 Congress, highlighting their SAR-bisPSMA product’s potential to improve imaging and treatment of prostate cancer. The study indicates significant detection capabilities in patients with biochemical recurrence of prostate cancer and a case report demonstrating a complete response in a patient with advanced prostate cancer. These developments mark a promising advance in Clarity’s mission to provide innovative cancer treatment options.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.